Strategic partnerships Circio is actively forming collaborations with multiple biotech players (Avenue Biosciences, GenAssist, Tcelltech, Aavigen) and academic partners (Karolinska Institutet). This indicates substantial partnership slots for co-development, licensing, or joint programs around circRNA platforms and circVec tech that sales teams can target.

Financial runway A NOK 300 million financing round completed in 2026 extends runway to end of 2030, providing Circio with ongoing funds to advance IND-enabling work and clinical proof-of-concept. This creates near-term opportunities for supplementary collaborations, milestone-based deals, or early access agreements tied to program milestones.

Tech integration Circio’s circVec circular RNA platform and partnerships focused on non-viral, non-integrating delivery and engineering of AAV vectors position them as a target for vendors offering complementary gene therapy delivery systems, vector design services, or manufacturing capabilities to scale up to IND-stage trials.

Therapeutic focus Current emphasis on immune activators, mutant RAS cancer vaccine programs, and heart disease gene therapies suggests sales opportunities with researchers and CROs in oncology and cardiovascular indications, as well as potential interest in in vivo cell therapy platforms and targeted gene delivery solutions.

Global collaboration Active cross-border collaborations in the US, Norway, China, and Germany indicate a willingness to engage with international partners. This opens doors for regional licensing deals, joint ventures, or sponsored research arrangements across diverse markets and regulatory environments.